09:43 AM EDT, 08/07/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) , up 1.6% in early trade, on Thursday said second-quarter net loss widened even as revenue rose.

The net loss widened to $12.6 million, or $0.13 per share, from $1.94 million, or $0.02 per share in the prior year quarter. This was due to higher general & administrative expenses, which increased 31%, and a revaluation of financial assets measured at fair value.

Revenue jumped 12% to $107.4 million over the same period. The increase was driven by Knight's key promoted products which grew by $13.5 million or 20% on a constant currency basis, purchasing patterns of certain products and incremental revenue of $2.4 million from the Paladin and Sumitomo transactions.

For fiscal 2025, Knight now expects to generate between $410 million to $420 million in revenue, up from $390 to $405 million. The increase in outlook is driven by the better performance in the first half and the incremental revenue from the license and supply agreements with Sumitomo.

The company's shares are up $0.10, to $6.39, on the Toronto Stock Exchange.

Price: 6.39, Change: +0.10, Percent Change: +1.59